Ledipasvir-d16

• Description:

  Ledipasvir-d16 (GS-5885-d16) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

• Product Name Alternative:

  GS-5885-d16

• UNSPSC:

  12352005

• Target:

  HCV; Isotope-Labeled Compounds; SARS-CoV

• Related Pathways:

  Anti-infection; Others

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Smiles:

  O=C (OC) NC (C (N ([C@@H] (C1=NC=C (C2=CC (C (F) (F) C3=C4C=CC (C5=CC=C6N=C ([C@@H]7N (C (C (NC (OC) =O) ([2H]) C (C ([2H]) ([2H]) [2H]) ([2H]) C ([2H]) ([2H]) [2H]) =O) [C@@]8 ([H]) CC[C@]7 ([H]) C8) NC6=C5) =C3) =C4C=C2) N1) C9) CC%109CC%10) =O) ([2H]) C (C ([2H]) ([2H]) [2H]) ([2H]) C ([2H]) ([2H]) [2H]

• Molecular Formula:

  C49H38D16F2N8O6

• Molecular Weight:

  905.10

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Link JO, et al. Discovery of ledipasvir (GS-5885) : a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57 (5) :2033-46|[3]Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013 May;57 (1) :13-8.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported